Tubulis

Drug Discovery · Planegg-Martinsried, Germany · Founded 2012 · Privately Held (backing)

Developer of chemotherapeutic drugs designed to fight against cancer and chronic diseases. Tubulis is based in Planegg-Martinsried, Germany and was founded in 2012. It was valued at $5.8 billion at a merger or acquisition in Apr 2026, the last priced event on record. It has raised $618 million across 1 recorded round; the latest was a $361 million Series C in Oct 2025.

PMV mark · valuation
$5.8B
Oct 2026
Priced at
a merger or acquisition
Apr 2026
Total raised
$618.5M
Last round
Later Stage VC (Series C)
Oct 2025
What is Tubulis worth?
$5.8BPrivateMarketView mark · Oct 2026

Valued at $5.8B at a merger or acquisition, Apr 2026. Nothing has traded since.

Free account
More of Tubulis with a free account
  • ·The complete investor list: 26 names
  • ·Everyone on the team, board and advisors included
  • ·Watch Tubulis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Tubulis funding history

1 rounds
DateRoundRaisedPost-money
Oct 2025Later Stage VC (Series C)$360.7M▮
Unlock post-money valuations

Membership and data by Private Market View

Tubulis valuation

Tubulis was valued at $5.8 billion at a merger or acquisition in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Tubulis raised?

Tubulis has raised $618 million in total; 1 of its rounds is on record. The largest on record was a $361 million Series C in Oct 2025.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Halda Therapeutics ($3 billion), Encoded Therapeutics ($1.8 billion) and Formation Bio ($1.7 billion).

How Tubulis's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Tubulis, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Tubulis

What is Tubulis worth?
Tubulis is valued at $5.8B as of Oct 2026. Valued at $5.8B at a merger or acquisition, Apr 2026. Nothing has traded since.
How much has Tubulis raised?
Tubulis has raised $618.5M in total funding across 1 recorded rounds.
When did Tubulis last raise?
Tubulis last raised in Oct 2025 (Later Stage VC (Series C)), raising $360.7M.